A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

NCT02276027 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma

Interventions

DRUG: BYL719
DRUG: INC280
DRUG: LDK378
DRUG: MEK162

Sponsor

Novartis Pharmaceuticals